In all four major trials, despite substantial statistical power to detect a clinically meaningful treatment effect, the administration of sitagliptin, saxagliptin, alogliptin and omarigliptin did not reduce the combined risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke [47,48,49,50]
Laboratory personnel must maintain proper documentation of the intended research use of these compounds
P.JohnC
Maintaining a healthy diet and regular exercise routine can help manage PCOS-related weight issues
It improves the ability to concentrate, learn, and memorize
The Food and Drug Administration began a probe into whether GLP-1s cause side effects like aspiration and hair loss in January, CBS News reports